Sign Out
Trumenba is indicated in individuals 10 years and older for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.
See Pharmacology: Pharmacodynamics under Actions for information on protection against specific serogroup B strains.
Dosing of Trumenba should be determined taking into consideration the risk of invasive meningococcal B disease by each country or region. The use of this vaccine should be in accordance with official recommendations.
Continue with Google